Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/20 10:55:00 am
449.825 DKK   -0.29%
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : UBS reiterates its Neutral rating

share with twitter share with LinkedIn share with facebook
09/25/2020 | 06:24am EDT

UBS's research confirms his advice and maintains his neutral opinion on the stock. The target price continues to be set at DKK 415.

© MarketScreener with dpa-AFX Analyser 2020

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S -0.03% 451 Delayed Quote.16.68%
UBS GROUP AG 2.65% 11.22 Delayed Quote.-10.59%
share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/14NOVO NORDISK : Buy rating from JP Morgan
MD
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
AQ
10/12NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020
PU
10/12NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..
AQ
10/12NOVO NORDISK A/S : – Share repurchase programme
AQ
10/09EUROPE : European stocks rack up second week of gains, Pandora leaps
RE
10/09NOVO NORDISK : Credit Suisse gives a Buy rating
MD
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
More news
Financials
Sales 2020 128 B 20 294 M 20 294 M
Net income 2020 42 192 M 6 705 M 6 705 M
Net cash 2020 10 613 M 1 687 M 1 687 M
P/E ratio 2020 25,0x
Yield 2020 2,00%
Capitalization 1 048 B 167 B 167 B
EV / Sales 2020 8,12x
EV / Sales 2021 7,60x
Nbr of Employees 43 526
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 451,00 DKK
Spread / Highest target 20,8%
Spread / Average Target -0,75%
Spread / Lowest Target -32,4%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S16.68%166 008
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-4.31%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349